TY - JOUR
T1 - Validity of the Patient Experiences and Satisfaction with Medications (PESaM) Questionnaire
AU - PESaM Collaborating Group
AU - Kimman, Merel L.
AU - Wijsenbeek, Marlies S.
AU - van Kuijk, Sander M.J.
AU - Wijnsma, Kioa L.
AU - van de Kar, Nicole C.A.J.
AU - Storm, Marjolein
AU - van Jaarsveld, Xana
AU - Dirksen, Carmen D.
AU - Bresser, Paul
AU - Coenen, Ilona
AU - Dijkstra, Nynke G.
AU - van Dooren, Brigitte A.A.
AU - Geelhoed, Miranda J.J.
AU - Gelens, Marielle
AU - de Haas, Kirsten
AU - Jonkers, René E.
AU - Koopman, Bart
AU - Kramer, Henk
AU - van Manen, Mirjam J.G.
AU - Miedema, Jelle R.
AU - Moor, Karen C.C.
AU - Mostard, Rémy L.M.
AU - Nossent, Esther J.
AU - Overbeek, Marieke J.
AU - Peeters, Ellen
AU - van Rijswijk, Rein H.N.A.J.
AU - Ryan, Helen
AU - Tak, Nelleke C.
AU - van Veen, Anneke
AU - Verhoeven, Lucyl
AU - de Vries, Michiel G.J.
AU - Wapenaar, Monique
AU - Wegman, Ingrid M.H.
AU - Wetzels, Jack
N1 - Funding Information: Funding This project was funded by The Federation of Patients and Consumer Organizations in the Netherlands (NPCF), Lung Foundation Netherlands, and The Netherlands Organization for Health Research and Development (ZonMw, Project Number 15200095001). Publisher Copyright: © 2018, The Author(s).
PY - 2019/2/4
Y1 - 2019/2/4
N2 - Background: This study assessed the validity and reliability of the generic module of the recently developed Patient Experiences and Satisfaction with Medications (PESaM) questionnaire in a sample of patients in the Netherlands. Methods: The generic module of the PESaM questionnaire consists of 18 items related to the domains effectiveness, side effects and ease of use of medications. It assesses patients’ experiences regarding the impact of the medication on daily life, health and satisfaction. In 2017, the PESaM questionnaire was sent out to idiopathic pulmonary fibrosis patients using pirfenidone or nintedanib, atypical haemolytic uraemic syndrome patients receiving eculizumab and patients using tacrolimus after kidney transplantation. Mean scores for each domain were calculated applying a scoring algorithm. Construct validity and reliability were assessed using recommended methods. Results: 188 participants completed the generic module, of whom 48% used pirfenidone, 36% nintedanib, 11% tacrolimus and 5% eculizumab. The generic module has good structural properties. Internal consistency values of the domains were satisfactory (i.e. Cronbach’s coefficient alpha above 0.7). Confirmatory factor analysis provided further evidence for construct validity, with good convergent and discriminant validity. The PESaM questionnaire also showed different scores for patients using different medications, in line with expectations, and was therefore able to differentiate between patient groups. Test–retest reliability of the items and domains were rated as moderate to fair (i.e. intraclass coefficients ranged between 0.18 and 0.76). Conclusions: The PESaM questionnaire is a unique patient-reported outcome measure evaluating patient experiences and satisfaction with medications. It has been developed in conjunction with patients, ensuring coverage of domains and issues relevant from the patient’s perspective. This study has shown promising validity of the generic module of the PESaM questionnaire. Further research is recommended to assess reliability in greater detail as well as the responsiveness of the measure. Trial registration: The study is registered in The Netherlands National Trial Register (Trial Code 5860).
AB - Background: This study assessed the validity and reliability of the generic module of the recently developed Patient Experiences and Satisfaction with Medications (PESaM) questionnaire in a sample of patients in the Netherlands. Methods: The generic module of the PESaM questionnaire consists of 18 items related to the domains effectiveness, side effects and ease of use of medications. It assesses patients’ experiences regarding the impact of the medication on daily life, health and satisfaction. In 2017, the PESaM questionnaire was sent out to idiopathic pulmonary fibrosis patients using pirfenidone or nintedanib, atypical haemolytic uraemic syndrome patients receiving eculizumab and patients using tacrolimus after kidney transplantation. Mean scores for each domain were calculated applying a scoring algorithm. Construct validity and reliability were assessed using recommended methods. Results: 188 participants completed the generic module, of whom 48% used pirfenidone, 36% nintedanib, 11% tacrolimus and 5% eculizumab. The generic module has good structural properties. Internal consistency values of the domains were satisfactory (i.e. Cronbach’s coefficient alpha above 0.7). Confirmatory factor analysis provided further evidence for construct validity, with good convergent and discriminant validity. The PESaM questionnaire also showed different scores for patients using different medications, in line with expectations, and was therefore able to differentiate between patient groups. Test–retest reliability of the items and domains were rated as moderate to fair (i.e. intraclass coefficients ranged between 0.18 and 0.76). Conclusions: The PESaM questionnaire is a unique patient-reported outcome measure evaluating patient experiences and satisfaction with medications. It has been developed in conjunction with patients, ensuring coverage of domains and issues relevant from the patient’s perspective. This study has shown promising validity of the generic module of the PESaM questionnaire. Further research is recommended to assess reliability in greater detail as well as the responsiveness of the measure. Trial registration: The study is registered in The Netherlands National Trial Register (Trial Code 5860).
UR - http://www.scopus.com/inward/record.url?scp=85055714977&partnerID=8YFLogxK
U2 - https://doi.org/10.1007/s40271-018-0340-6
DO - https://doi.org/10.1007/s40271-018-0340-6
M3 - Article
C2 - 30367435
SN - 1178-1653
VL - 12
SP - 149
EP - 162
JO - Patient
JF - Patient
IS - 1
ER -